title: Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
authors.affiliation: National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD, USA.
authors.forename: A Dimitrios
authors.initials: AD
authors.lastname: Colevas
authors.forename: Orit
authors.initials: O
authors.lastname: Scharf
authors.forename: Mason
authors.initials: M
authors.lastname: Schoenfeldt
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D039564:Integrin alphaV / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy; D012910:Snake Venoms / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D039564:Integrin alphaV; D012910:Snake Venoms; C422910:Cilengitide